Cancer/Tumor Profiling Market by Technology, Biomarker Type, Cancer Type, Application - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation

Description

List of Tables

The Global Cancer/Tumor Profiling Market is forecasted to grow significantly, with a projected USD 10,798.54 million in 2023 at a CAGR of 18.67% and expected to reach a staggering USD 35,944.38 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Cancer/Tumor Profiling Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Cancer/Tumor Profiling Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Technology, market is studied across Immunoassays, In-Situ Hybridization, Mass Spectrometry, Microarrays, Next-Generation Sequencing, and Polymerase Chain Reaction. The Next-Generation Sequencing commanded largest market share of 24.12% in 2022, followed by Immunoassays.

Based on Biomarker Type, market is studied across Genomic Biomarker and Protein Biomarker. The Genomic Biomarker commanded largest market share of 58.77% in 2022, followed by Protein Biomarker.

Based on Cancer Type, market is studied across Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma Cancer, and Prostate Cancer. The Lung Cancer commanded largest market share of 23.23% in 2022, followed by Breast Cancer.

Based on Application, market is studied across Biomarker Discovery, Clinical Application, Diagnostics, Personalized Medicine, Prognostics, Research, Screening, and Treatment & Monitoring. The Diagnostics commanded largest market share of 22.12% in 2022, followed by Personalized Medicine.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 39.45% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Cancer/Tumor Profiling Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Cancer/Tumor Profiling Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cancer/Tumor Profiling Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cancer/Tumor Profiling Market?

4. What is the competitive strategic window for opportunities in the Global Cancer/Tumor Profiling Market?

5. What are the technology trends and regulatory frameworks in the Global Cancer/Tumor Profiling Market?

6. What is the market share of the leading vendors in the Global Cancer/Tumor Profiling Market?

7. What modes and strategic moves are considered suitable for entering the Global Cancer/Tumor Profiling Market?

Product Code: MRR-374DB5A06C9C

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Cancer/Tumor Profiling Market, by Technology, 2022 vs 2030
4.3. Cancer/Tumor Profiling Market, by Biomarker Type, 2022 vs 2030
4.4. Cancer/Tumor Profiling Market, by Cancer Type, 2022 vs 2030
4.5. Cancer/Tumor Profiling Market, by Application, 2022 vs 2030
4.6. Cancer/Tumor Profiling Market, by Region, 2022 vs 2030

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing adoption of biomarkers to treat cancer patients
  - 5.1.1.2. Availability of government and global organizations' initiatives for devising cancer diagnosing methods
  - 5.1.1.3. Surging preference for personalized medicines for cancer treatment
- 5.1.2. Restraints
  - 5.1.2.1. High capital investment in cancer/tumor profiling instruments and services
- 5.1.3. Opportunities
  - 5.1.3.1. Emergence of next-generation sequencing and advancements in tumor profiling
  - 5.1.3.2. Improvements in point-of-care diagnostic technologies to improve cancer detection
- 5.1.4. Challenges
  - 5.1.4.1. Low biomarker discovery-to-approval ratio
5.2. Market Trends
- 5.2.1. Government initiatives for cancer diagnostics with rapid advancements in cancer/tumor profiling solutions
- 5.2.2. Rising cancer prevalence with evolving cancer research initiatives enhancing the need for novel cancer/tumor profiling in the APAC region
- 5.2.3. Increasing adoption of precision medicines and genetic profiling solutions to overcome the cancer burden across EMEA region
5.3. Cumulative Impact of COVID-19
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter's Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework
5.9. Client Customization

6. Cancer/Tumor Profiling Market, by Technology

6.1. Introduction
6.2. Immunoassays
6.3. In-Situ Hybridization
6.4. Mass Spectrometry
6.5. Microarrays
6.6. Next-Generation Sequencing
6.7. Polymerase Chain Reaction

7. Cancer/Tumor Profiling Market, by Biomarker Type

7.1. Introduction
7.2. Genomic Biomarker
7.3. Protein Biomarker

8. Cancer/Tumor Profiling Market, by Cancer Type

8.1. Introduction
8.2. Breast Cancer
8.3. Colorectal Cancer
8.4. Lung Cancer
8.5. Melanoma Cancer
8.6. Prostate Cancer

9. Cancer/Tumor Profiling Market, by Application

9.1. Introduction
9.2. Biomarker Discovery
9.3. Clinical Application
9.4. Diagnostics
9.5. Personalized Medicine
9.6. Prognostics
9.7. Research
9.8. Screening
9.9. Treatment & Monitoring

10. Americas Cancer/Tumor Profiling Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Cancer/Tumor Profiling Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Cancer/Tumor Profiling Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
- 13.3.1. Merger & Acquisition
  - 13.3.1.1. Agilent Announces Acquisition of Avida Biomed, Developer of High-Performance NGS Target Enrichment Workflows for Cancer Research
  - 13.3.1.2. Prenetics Acquires ACT Genomics
- 13.3.2. Agreement, Collaboration, & Partnership
  - 13.3.2.1. Sophia Genetics, Agilent Partner on Cancer Analysis Product
  - 13.3.2.2. Point32Health and Foundation Medicine Expand Access to Comprehensive Genomic Profiling for Members with Advanced Cancer
- 13.3.3. New Product Launch & Enhancement
  - 13.3.3.1. Synergy Laboratories Taps SOPHiA GENETICS Technology for New Cancer Profiling Solution
  - 13.3.3.2. Exact Sciences Launches OncoExTra Cancer Therapy Selection Test in the U.S.
- 13.3.4. Investment & Funding
  - 13.3.4.1. Caris Life Sciences nears USD 2B in total funding with USD 400M haul
  - 13.3.4.2. CDC Awards USD 215 Million to Advance Cancer Moonshot Goals
- 13.3.5. Award, Recognition, & Expansion
  - 13.3.5.1. Prenetics Owned ACT Genomics Receives FDA Clearance for ACTOnco
  - 13.3.5.2. Roche receives FDA approval for first companion diagnostic to identify patients with HER2 low metastatic breast cancer eligible for Enhertu

14. List of Company Mentioned

15. Appendix

15.1. Discussion Guide
15.2. License & Pricing